Obeticholic acid, commercially known as Ocaliva, is a prescription medication developed by Intercept Pharmaceuticals for the treatment of primary biliary cholangitis.
Here are three of the upcoming presentations:
1. “Predicted Risk of End Stage Liver Disease with Continued Standard of Care and Subsequent Addition of Obeticholic Acid in Patients with PBC”
2. “Long-Term Effect of Obeticholic Acid on Transient Elastography and AST to Platelet Ratio Index in Patients with PBC”
3. “Obeticholic acid, a synthetic FXR agonist, prevents hepatic inflammation and fibrosis in a novel mouse model of non-alcoholic steatohepatitis”
There will be a total of 11 presentations on obeticholic acid at the meeting.
More articles on gastroenterology and endoscopy:
Aspirin reduces risk of tumors with low levels of tumor-infiltrating lymphocytes: 3 study insights
AGA, Asociación Mexicana de Gastroenterología to host joint symposium for Mexican Gastroenterology Week: 3 notes
Inflammatory bowel disease 3 times more common than previous estimates: 5 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.